BNP Paribas downgraded Organon (OGN) to Neutral from Outperform with a $14 price target after the company entered into an agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14 per share in an all-cash transaction
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: